A federal jury in Delaware awarded Merck $2.54 billion in royalties over Gilead's Sovaldi and Harvoni hepatitis C drugs for infringing Merck's patent. The jury awarded Merck a royalty rate of 10% on total sales of $25.4 billion. The verdict can be found here: http://bit.ly/2gRtMqw
No comments:
Post a Comment